News | Oncology Diagnostics | October 25, 2017

Researchers Discover New Blood Test That May Diagnose Breast Cancer

Christiana Care and GenPro file for provisional patent on novel screening tool

Researchers Discover New Blood Test That May Diagnose Breast Cancer

October 25, 2017 — In a potential major breakthrough in breast cancer research, scientists at the Center for Translational Cancer Research (CTCR) at the Helen F. Graham Cancer Center & Research Institute of Christiana Care Health System have developed a new blood test to diagnose breast cancer.

Senior scientist Jennifer Sims-Mourtada, Ph.D., director of translational breast cancer research at the CTCR located in Newark, Del, developed the test at the CTCR with scientists from Genome Profiling LLC (GenPro).

“This simple blood test, used in combination with mammography, can be a transformative tool in the fight against breast cancer by determining whether cancer is present in the breast and whether the cancer is likely to spread,” Sims-Mourtada said. “Using this test could minimize over-diagnosis and treatment while potentially providing significant savings in healthcare-related costs. Studies have shown that mammograms alone are not optimal for diagnosing all types of breast cancer.”

The test focuses on identifying an epigenetic biomarker within circulating blood cells’ DNA that are part of the body’s immune system and is different from other diagnostic tests that target cancer tumors.

“This test is designed to monitor epigenetic DNA changes in the blood cells that could signal an early stage aggressive tumor,” Sims-Mourtada said. “We know that immune cells in the blood react differently if they are responding to an infection versus a cancer, an invasive tumor or when there is no cancer present at all.”

“Commercializing an epigenetic-based diagnostic test into a simple and cost-effective blood screening test can have huge implications for early intervention strategies in breast cancer,” said GenPro co-founder Adam Marsh, Ph.D. GenPro is a molecular information company specializing in the discovery of novel epigenetic biomarkers using its genome-wide profiling platform.

“Right now there is no truly effective method for routine monitoring of patients to follow in response to treatment for breast cancer and for possible recurrence of cancer,” Sims-Mourtada said. “Using the assay we have developed, in conjunction with routine monitoring, enables us to follow changes in the immune response to detect an increase in tumor cells over time. This test can allow for much earlier detection of recurrence or metastatic disease before it is visible with standard imaging and enable much earlier treatment.”

Christiana Care and GenPro have filed a provisional patent application with the U.S. Patent and Trademark Office as the first step in the process toward clinical trials and U.S. Food and Drug Administration (FDA) approval for this new blood screening test.

For more information: www.christianacare.org

Related Content

Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
"Where's My Mammogram?" Campaign Helps Women Own Breast Health Records
News | Breast Imaging | October 10, 2018
October 10, 2018 — Mammosphere launched “Where’s My Mammogram?,” a public service campaign to help women obtain copie
DenseBreast-info.org Launches European Expansion
News | Breast Density | October 10, 2018
DenseBreast-info.org (DB-I) announced the launch of its international expansion for European medical providers. The...
X-ray Mammography Adoption to Skyrocket for Breast Cancer Detection
News | Mammography | October 08, 2018
Highly populated countries have traditionally been slow adopters of non-conventional business models, but a new Frost...
Body Vision Medical Announces Release of LungVision
Technology | Lung Cancer | October 05, 2018
Body Vision Medical, a medical device company specializing in lung cancer diagnostics, announced the launch of its...
Cullman Regional Medical Center

Cullman Regional Medical Center (Alabama) is a 145-bed medical center serving more than 175,000 residents in a six-county area and recognized as one of the region’s finest medical facilities.

Sponsored Content | Case Study | PACS | October 05, 2018
When Cullman Regional Medical Center in Alabama decided to switch from 2-D
Feature | Mammography | October 05, 2018 | By Jeff Zagoudis
“Patient-centered care” is a popular term among those in the healthcare industry in the 21st century. It means the...
Feature | Breast Imaging | October 04, 2018 | By Tracy Accardi
It has been nearly eight years since the world’s first digital breast tomosynthesis (DBT) mammography technology was...
Leica Biosystems Launches MammoPort Specimen Containment and Transport System
Technology | Breast Biopsy Systems | October 03, 2018
Leica Biosystems announced the U.S. launch of MammoPort, the first integrated specimen containment and transport system...
Adherence to Annual Lung Cancer Screening Needs Improvement
News | Lung Cancer | October 03, 2018
A study of adherence to annual low-dose computed tomography (LDCT) screening within the Veteran Health Administration...